PRO Pfizer/Flynn Pharma and excessive pricing – a case study

David Hull discusses the implications of Pfizer/Flynn Pharma's successful appeal against a 2016 ruling of excessive pricing.

About

David Hull

Van Bael & Bellis
David Hull
  • Posted 30 November 2018
  • Duration 5:48 min
  • Language English

Tags